Disc Medicine (NASDAQ:IRON – Get Free Report)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $85.00 price target on the stock. Cantor Fitzgerald’s target price points to a potential upside of 77.12% from the stock’s previous close.
A number of other research firms have also recently commented on IRON. Wells Fargo & Company started coverage on Disc Medicine in a research report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $57.00 price objective on shares of Disc Medicine in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Disc Medicine in a report on Monday, September 16th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $70.00 target price (up from $50.00) on shares of Disc Medicine in a report on Monday, June 17th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $63.89.
View Our Latest Research Report on Disc Medicine
Disc Medicine Stock Up 0.7 %
Disc Medicine (NASDAQ:IRON – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. Analysts anticipate that Disc Medicine will post -4.19 earnings per share for the current year.
Hedge Funds Weigh In On Disc Medicine
Large investors have recently added to or reduced their stakes in the company. Amalgamated Bank increased its stake in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after purchasing an additional 247 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Disc Medicine in the 2nd quarter worth $129,000. SG Americas Securities LLC increased its stake in Disc Medicine by 44.2% in the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock worth $183,000 after buying an additional 1,247 shares in the last quarter. ProShare Advisors LLC bought a new stake in Disc Medicine during the first quarter valued at about $211,000. Finally, Algert Global LLC purchased a new position in shares of Disc Medicine in the second quarter valued at about $239,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.
About Disc Medicine
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Featured Articles
- Five stocks we like better than Disc Medicine
- Trading Stocks: RSI and Why it’s Useful
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- 3 Healthcare Dividend Stocks to Buy
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.